Presentation on theme: "Bacterial Meningitis Vaccines and the Prevention of Meningitis in Cochlear Implant Recipients Karen Broder, M.D. Epidemic Intelligence Service Officer."— Presentation transcript:
Bacterial Meningitis Vaccines and the Prevention of Meningitis in Cochlear Implant Recipients Karen Broder, M.D. Epidemic Intelligence Service Officer National Immunization Program Centers for Disease Control and Prevention February 24, 2003
US Meningitis Vaccines Haemophilus influenzae Type b Conjugate (Hib) (several brands) Meningococcal Polysaccharide (Menomune®) Pneumococcal Polysaccharide (Pneumovax®) Pneumococcal Conjugate (Prevnar®)
Recommended Childhood and Adolescent Immunization Schedule, US 2003 http://www.cdc.gov/nip/recs/child-schedule.htm
Haemophilus influenzae Type b (Hib) Vaccine Universal immunization for children aged <5 years High-risk indications for persons aged 5 years –Immune system disorders
Meningococcal Vaccine Not universal immunization High-risk indications usually for persons aged 2 years –Travel to endemic country –Outbreak control –College Freshman living in dorm (often optional) –Immune system disorders
Pneumococcal Polysaccharide Vaccine (PPV23) Universal immunization for adults aged 65 years High-risk indications for persons aged 2-64 years –Immune system disorders –Residence in special environments or social settings –Chronic medical conditions
Public Health Response Meningitis Vaccination and Cochlear Implant Recipients Reviewed meningitis vaccination recommendations Disseminated vaccination information to stakeholders –Cochlear implant recipients –State health departments –Health care providers
Immunization Response to Cochlear Implants and Meningitis Association Could vaccination decrease the risk of meningitis among cochlear implant recipients?
Review of Vaccination Policy Vaccine-preventable cause? –Yes, pneumococcus Biological plausibility? –Yes, potential anatomic pathways and other mechanisms
Review of Vaccination Policy Applicable ACIP high-risk indication? –Yes, pneumococcal vaccination for persons with CSF leaks Accessibility concerns? –Yes, national PCV7 vaccine shortage
CDC Recommendation for Cochlear Implant Recipients: High-Risk Pneumococcal Vaccination
Information Resources Cochlear Implants and Vaccination NIP Website –General public http://www.cdc.gov/nip/issues/cochlear/cochlear-gen.htmhttp://www.cdc.gov/nip/issues/cochlear/ –Health care provider http://www.cdc.gov/nip/issues/cochlear/ http://www.cdc.gov/nip/issues/cochlear/ cochlear-hcp.htm National Immunization Hotline –English (800)232-2522 –Spanish (800)232-0233 –TTY (800)243-7889
Pneumococcal Vaccination Schedule for Unvaccinated Cochlear Implant Recipients Age in Years PCV7*PPV23** <2 2-4 5 * ACIP Age-appropriate high-risk schedules should be followed ** PPV23 and PCV7 should be administered 2 months apart.
Vaccination for Cochlear Implant Recipients Four bacterial meningitis vaccines covering three causes of meningitis No initial specific vaccination recommendations Current pneumococcal vaccination recommendations Following study need to reevaluate vaccination recommendations
Acknowledgments Cochlear Implant Team including: J. Reefhuis, M. Honein, S. Chamany, K. Biernath, C. Whitney, E. Mann, S. Manning, S. Avashia, M. Victor, B. Culpepper, P. Costa, and C. Boyle Immunization Team including: J. Moran, B. Schwartz, T. Murphy, K. Bisgard, M. Wharton, L. Pickering, M. Bailey, the State Immunization Coordinators and the National Immunization Hotline